BRIAN LEE: Open Payments
NPI 1881768596 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$250 in 11 payments from 9 companies in 2025. Trend: 2023 $276 · 2024 $331 · 2025 $250
Food & beverage: $250
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 2 | $49 |
| Amgen Inc. | 2 | $45 |
| Forte Bio-Pharma LLC | 1 | $31 |
| Abbott Laboratories | 1 | $28 |
| Averitas Pharma Inc. | 1 | $26 |
| Dexcom, Inc. | 1 | $21 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $19 |
| AstraZeneca Pharmaceuticals LP | 1 | $16 |
| Orexo US, Inc. | 1 | $15 |
Products named: OTEZLA, PROLATE, FREESTYLE LIBRE 3, QUTENZA, Dexcom G6 Transmitter, Kerendia, AIRSUPRA, Zubsolv.
Industry payments across NV — which companies pay providers there.
